Table 3 Univariate analysis of factors associated with long-term outcomes (n = 44)

Sex

 Female

19

77.2% ± 10.2%

66.2% ± 11.4%

23.9% ± 10.6%

 Male

25

72.3% ± 10.0%

63.0% ± 10.9%

33.0% ± 10.7%

WBC(× 10⁹/L)

 < 50

23

82.6% ± 7.9%

70.7% ± 10.4%

25.0% ± 9.9%

 ≥ 50

17

66.8% ± 15.0%

57.0% ± 13.9%

31.2% ± 13.2%

Haplo-HSCT

 No

7

85.7% ± 13.2%

42.9% ± 31.0%

57.1% ± 31.0%

 Yes

37

73.0% ± 7.9%

65.6% ± 8.2%

26.4% ± 7.7%

Age(years)

 < 10

24

87.3% ± 6.9%

64.5% ± 11.9%

31.4% ± 11.6%

 ≥ 10

20

60.0% ± 12.0%

61.4% ± 11.8%

28.6% ± 11.1%

MRD + at pre-HSCT

 No

29

89.7% ± 5.7%

81.4% ± 7.6%

11.7% ± 6.4%

 Yes

15

48.5% ± 13.8%

34.3% ± 13.3%

59.0% ± 13.8%

CNS infiltration

 No

37

78.3% ± 7.5%

68.1% ± 8.7%

23.9% ± 8.2%

 Yes

7

57.1% ± 18.7%

42.9% ± 18.7%

57.1% ± 18.7%

AF9

 No

34

78.5% ± 8.0%

68.7% ± 9.1%

25.6% ± 8.7%

 Yes

10

60.0% ± 15.5%

50.0% ± 15.8%

40.0% ± 15.5%

EVI1 Expression

 No

36

71.4% ± 8.4%

63.9% ± 8.5%

27.8% ± 8.0%

 Yes

8

87.5% ± 11.7%

70.0% ± 18.2%

30.0% ± 18.2%

FLT3-ITD mutations

 No

37

75.9% ± 7.6%

65.9% ± 8.7%

28.8% ± 8.4%

 Yes

7

68.6% ± 18.6%

57.1% ± 18.7%

28.6% ± 17.1%

1 cycle to CR

 No

17

64.2% ± 11.8%

37.3% ± 12.5%

50.9% ± 12.9%

 Yes

27

80.7% ± 90.0%

82.6% ± 8.1%

13.7% ± 7.5%

MRD- after 2 cycles

 No

21

70.2% ± 10.2%

54.9% ± 11.3%

40.4% ± 11.2%

 Yes

23

82.6% ± 7.9%

77.4% ± 8.9%

13.9% ± 7.5%

II-IV aGVHD

 No

32

83.2% ± 6.9%

74.7% ± 8.6%

22.3% ± 8.3%

 Yes

12

43.8% ± 20.2%

37.5% ± 15.3%

45.8% ± 15.7%

cGVHD

 No

28

69.5% ± 9.2%

61.0% ± 10.0%

28.3% ± 9.3%

 Yes

16

83.3% ± 10.8%

70.0% ± 12.9%

30.0% ± 12.9%